Mercier Ythier Jean
Sorbonne Université, Paris, France Université Panthéon-Assas, Paris, France.
Biomed Mater Eng. 2015;25(1 Suppl):199-209. doi: 10.3233/BME-141251.
Recent advances of fundamental research on the in vitro generation of red blood cells (RBCs) from hematopoietic stem cells in the laboratory open new possibilities of the utilization of cultured RBCs in transfusion medicine. We study the economic challenge of the setup and development of the mass industrial production of RBCs in mature transfusion organizations. We argue that: (i) RBC manufacturing could be set up and developed in the short-medium run for the treatment of the small proportion of transfused patients who have a rare blood type or are alloimmunized against blood antigens; (ii) manufactured RBCs could substitute for donated RBCs in the long run if the physical productivity of RBC engineering technology approaches that of bone marrow.
实验室中从造血干细胞体外生成红细胞（RBCs）的基础研究取得的最新进展，为输血医学中利用培养的红细胞开辟了新的可能性。我们研究了成熟输血机构大规模工业化生产红细胞的建立和发展所面临的经济挑战。我们认为：（i）在短期至中期内，可以建立和发展红细胞制造技术，用于治疗一小部分血型罕见或对血液抗原产生同种免疫的输血患者；（ii）如果红细胞工程技术的实际生产力接近骨髓的生产力，从长远来看，制造的红细胞可以替代捐赠的红细胞。
